NCT05643781View on ClinicalTrials.gov

Tuberculosis as a Risk Factor for a Worse Outcome Post-Sars-CoV-2 Infection

CompletedOBSERVATIONAL
Enrollment

157

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
COVID-19TuberculosisPost-acute COVID-19 Syndrome
Trial Locations (1)

2193

The Aurum Institute, Johannesburg

All Listed Sponsors
collaborator

Chris Hani Baragwanath Academic Hospital

OTHER

collaborator

Ludwig-Maximilians - University of Munich

OTHER

lead

The Aurum Institute NPC

OTHER

NCT05643781 - Tuberculosis as a Risk Factor for a Worse Outcome Post-Sars-CoV-2 Infection | Biotech Hunter | Biotech Hunter